title: Characterization and NH2-terminal amino acid sequence of natural human interleukin for DA cells: leukemia inhibitory factor. Differentiation inhibitory activity secreted by a T lymphoma cell line.
abstract: Six human T lymphomas and an NK-like cell line were tested for their ability to produce HILDA, one of the two human growth promoting activities for the DA1.a cells. Among them, the HSB2 cell line turned out to be the only one secreting significant HILDA activity (200-400 units/ml) after activation with 50 nM phorbol myristate acetate. Subclones of the HSB2 cell line were obtained by limiting dilution experiments. One of them (2B3) was found to secrete 1,000-5,000 units/ml of HILDA after phorbol myristate acetate activation in the presence of 10% fetal calf serum and 200-500 units/ml in serum-free conditions. 2B3-HILDA was purified from serum-free conditioned medium by a four-step procedure including fast flow cationic exchange at pH 6, concanavalin A chromatography, reverse-phase high performance liquid chromatography and gel-filtration high performance liquid chromatography. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of the purified radiolabeled cytokine revealed a single band of Mr 43,000, which co-electrophoresed with the biological activity. The NH2-terminal amino acid sequence of the first residues of the protein were determined and found to be similar to the equivalent residues deduced from the molecularly cloned cytokine. Isoelectric point determination revealed some charge heterogeneity of HILDA, which focused to pH 8.5-9 after neuraminidase treatment. Carbohydrate content of the cytokine was studied by deglycosylation experiments which showed that the O-linked oligosaccharides represented 2,000-3,000 and that the N-linked sugars account for half of the apparent molecular weight of HILDA.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale Unité 211, Faculté de Médecine, Nantes, France.
authors.forename: H
authors.initials: H
authors.lastname: Gascan
authors.forename: A
authors.initials: A
authors.lastname: Godard
authors.forename: C
authors.initials: C
authors.lastname: Ferenz
authors.forename: J
authors.initials: J
authors.lastname: Naulet
authors.forename: V
authors.initials: V
authors.lastname: Praloran
authors.forename: M A
authors.initials: MA
authors.lastname: Peyrat
authors.forename: R
authors.initials: R
authors.lastname: Hewick
authors.forename: Y
authors.initials: Y
authors.lastname: Jacques
authors.forename: J F
authors.initials: JF
authors.lastname: Moreau
authors.forename: J P
authors.initials: JP
authors.lastname: Soulillou
mesh_terms: D000595:Amino Acid Sequence; D002454:Cell Differentiation / Q000187:drug effects*; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002846:Chromatography, Affinity; D002850:Chromatography, Gel; D002851:Chromatography, High Pressure Liquid; D006131:Growth Inhibitors / Q000235:genetics* / Q000302:isolation & purification / Q000494:pharmacology; D006801:Humans; D015850:Interleukin-6; D007378:Interleukins / Q000235:genetics*; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines; D008223:Lymphoma; D008969:Molecular Sequence Data; D008970:Molecular Weight; D009844:Oligosaccharides / Q000032:analysis; D014407:Tumor Cells, Cultured / Q000502:physiology*
chemical_list: D006131:Growth Inhibitors; D015850:Interleukin-6; D007378:Interleukins; C507837:LIF protein, human; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines; D009844:Oligosaccharides